GLP—1 下半场生变:辉瑞抢跑 诺和诺德与药王渐行渐远?

华夏时报网
Feb 26

全球GLP—1 赛道格局生变,曾经的行业霸主诺和诺德正遭遇重大危机。作为胰岛素领域巨头,诺和诺德全力研发的新一代减重药CagriSema,在头对头试验中数据不敌礼来的替尔泊肽,引发其股价狂泄,美股单日暴跌超16%,创下2021年6月以来的最低收盘纪录。  更为严峻的是,双雄并立的GLP—1赛道又切入新玩家辉瑞。在国内市场,辉瑞获得杭州先为达生物埃诺格鲁肽注射液的中国大陆独家商业化权益。国际市场上,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10